<DOC>
	<DOCNO>NCT00409006</DOCNO>
	<brief_summary>The purpose study compare efficacy safety chemotherapy follow sequentially gefitinib versus chemotherapy alone first line treatment non-small cell lung cancer ( NSCLC ) . This study conduct Asian patient classify 'never smoker ' since suggest patient likely respond favorably treatment gefitinib .</brief_summary>
	<brief_title>Chemotherapy Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis nonsmall cell lung cancer ( NSCLC ) ( Stage IIIB IV ) Have receive prior chemotherapy , molecular therapy , immunotherapy , biological therapy , radiotherapy . Exception : palliative radiotherapy complete least 4 week prior study enrolment . Have 'never smoke ' ( define smoke &lt; 100 cigarette his/her lifetime ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Concurrent administration tumor therapy Other coexist malignancy Pregnancy breast feed Serious concomitant disorder Inability unwillingness take folic acid vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>